Dan Barouch, MD
Infectious Disease · Boston, MANPI 1992786974
Payments from drug & device makers
What this record shows
That places this record below the midpoint for infectious disease clinicians in MA, where the typical reported total is $42.
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
Across 73 payments — averaging $490,311 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$13.4M
- Johnson & Johnson$10.5M
- Gilead$7M
- Pfizer$4.7M
- Alkermes, Inc.$263K
- Regeneron$1K
- plus $60 from 1 others
How this compares
$0 in reported general payments places this provider in the 35th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Boston
- Yoav GolanBoston$1.1M
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Paul SaxBoston$320K
- Davidson HamerBoston$221K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Eric RosenbergBoston$134K
- Deborah HungBoston$130K
- Laura KogelmanBoston$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.